Works Published in 1995
Displaying all 2 works
Sorted by most recent date added to the index first, which may not be the same as publication date order.
1995 journal article
Genetic alterations cooperate with v-Ha-ras to accelerate multistage carcinogenesis in TG.AC transgenic mouse skin
Cancer Research, 55(14), 3171–3178.
Sources: NC State University Libraries, ORCID
Added: May 5, 2022
1995 journal article
Lack of effect of retinoic acid and fluocinolone acetonide on mirex tumor promotion indicates a novel mirex mechanism
Carcinogenesis, 16(9), 2199–2204.
MeSH headings : 9,10-Dimethyl-1,2-benzanthracene / toxicity; Animals; Anticarcinogenic Agents / therapeutic use; Base Sequence; Carcinogens / toxicity; Cell Division / drug effects; Drug Interactions; Ear, External / drug effects; Edema / chemically induced; Edema / drug therapy; Female; Fluocinolone Acetonide / therapeutic use; Genes, ras / drug effects; Genotype; Mice; Mice, Inbred Strains; Mirex / antagonists & inhibitors; Mirex / toxicity; Molecular Sequence Data; Papilloma / chemically induced; Papilloma / prevention & control; Skin Neoplasms / chemically induced; Skin Neoplasms / prevention & control; Tetradecanoylphorbol Acetate / toxicity; Tretinoin / therapeutic use
TL;DR:
Results indicate that the promotional activity of mirex, as well as its weak proliferative response, result from a distinct promoter mechanism and/or that mireX promotes a unique population of epidermal cells that are insensitive to FA and RA and cannot be distinguished by their mutant Ha-ras genotype.
(via Semantic Scholar)
UN Sustainable Development Goal Categories
3. Good Health and Well-being
(Web of Science)
Sources: Crossref, ORCID
Added: April 9, 2022
Citation Index includes data from a number of different sources. If you have questions about the sources of data in the Citation Index or need a set of data which is free to re-distribute, please contact us.
Certain data included herein are derived from the Web of Science© and InCites© (2024) of Clarivate Analytics. All rights reserved. You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
